Company intelligence / Profile preview

Capturo

Ownership: Private
Development stage: Other

Overview

Captura Biopharma is developing C2E2, an oral solution designed to rapidly eliminate harmful radioactive materials from the body following nuclear incidents. The company aims to provide a scalable alternative to IV-based treatments for radiation exposure, especially in mass casualty scenarios. No published clinical results are available yet.

Therapeutic areas: Other
Modalities: Small molecule (oral solution)
Industry: Biotech

Beyond the preview

Go deeper on Capturo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capturo.

Explore the full profile